HDT Bio Analysis: $15M Raised
What is HDT Bio?
HDT Bio develops next-generation immunotherapies using proprietary LION™ technology to treat and prevent cancer and infectious diseases. The platform enhances immune system potency, safety, and durability. FDA has approved HDT-321 for preventing tick-borne diseases. LION™ technology licensed to MalarVx for malaria vaccine development.
Location
Seattle, United States
Employees
51-200
Founded
2018
Funding Status
Seed
Product Features & Capabilities
- LION™ RNA immunotherapy for cancer
- LION™ RNA immunotherapy for infectious diseases
- HDT-321 for tick-borne disease prevention
- repRNA/LION™ technology for malaria vaccine development
Use Cases
Treat advanced cancers with LION™ RNA therapy; Prevent tick-borne diseases with HDT-321; Develop novel malaria vaccine using repRNA/LION™ technology; Provide immune-boosting therapy for patients with immunodeficiencies; Enable global health solutions for emerging infectious diseases
Other Considerations
FDA greenlights HDT-321 for tick-borne disease prevention; LION™ technology licensed to MalarVx for malaria vaccine development; Clinical stage biotech with active pipeline in oncology and infectious diseases; Proprietary LION™ platform with superior safety and durability; Active in global health and biodefense initiatives
See something that needs updating? Suggest edits to this profile.